<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620148</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-242-2001</org_study_id>
    <nct_id>NCT04620148</nct_id>
  </id_info>
  <brief_title>TAK-242 in Patients With Acute Alcoholic Hepatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subjects With Acute Alcoholic Hepatitis Causing Decompensation of Alcohol-related Cirrhosis and Acute-on-Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akaza Bioscience Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akaza Bioscience Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study&#xD;
      to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in&#xD;
      subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis&#xD;
      resulting in acute-on-chronic liver failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CLIF-C ACLF score from baseline to Day 8</measure>
    <time_frame>Baseline to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who experience at least 1 markedly abnormal treatment-emergent AE or SAE</measure>
    <time_frame>To Day 28</time_frame>
    <description>The percentage of subjects who experience at least 1 treatment-emergent AE or SAE that meets the Sponsor's markedly abnormal criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who experience at least 1 treatment-emergent clinical laboratory test result or abnormal ECG that meets the Sponsor's markedly abnormal criteria</measure>
    <time_frame>To Day 28</time_frame>
    <description>The percentage of subjects who experience at least 1 treatment-emergent clinical laboratory test result or abnormal ECG that meets the Sponsor's markedly abnormal criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who discontinue study drug due to an AE</measure>
    <time_frame>To Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in naturally log-transformed key biomarkers</measure>
    <time_frame>Baseline to day 8</time_frame>
    <description>Change in naturally log-transformed key biomarkers (TB, IL-8, high sensitivity CRP [hs-CRP], and urinary NGAL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at Day 28 after initiation of TAK-242 therapy versus placebo</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>TAK-242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered TAK-242 as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be administered placebo as a continuous IV infusion with standard care starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-242</intervention_name>
    <description>TAK-242 concentrate solution 80 mg/mL for dilution and infusion</description>
    <arm_group_label>TAK-242</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo concentrate solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of alcohol-related cirrhosis who continue to drink heavily&#xD;
&#xD;
          -  History of an acute decompensating event with a clinical and/or liver biopsy diagnosis&#xD;
             of alcoholic hepatitis&#xD;
&#xD;
          -  Grade 1 or 2 ACLF using the CLIF-C OF score; OR bilirubin criteria OR criteria of&#xD;
             acute kidney injury Stage 1b or 2 after initial supportive treatment with fluids,&#xD;
             albumin, or terlipressin; AND CLIF-C ACLF score is &gt;35 and &lt;64&#xD;
&#xD;
          -  History of alcohol-related cirrhosis based on clinical, radiological, and/or&#xD;
             histological evidence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received certain previous therapies (any investigational drug within 30 days of&#xD;
             randomization, corticosteroids for alcohol-induced liver failure within 4 weeks of&#xD;
             randomization, or received TAK-242 in any previous study)&#xD;
&#xD;
          -  History of liver cirrhosis from other chronic diseases; liver failure from other&#xD;
             causes&#xD;
&#xD;
          -  History of liver transplantation, post-operative decompensation after partial&#xD;
             hepatectomy, acute or subacute liver failure without underlying cirrhosis&#xD;
&#xD;
          -  Any untreated infections including gram-positive infections, or active or latent&#xD;
             atuberculosis, sepsis or septic shock, or coinfection with hepatitis B virus,&#xD;
             hepatitis C virus, hepatitis E virus, or HIV&#xD;
&#xD;
          -  Chronic or pre-existing kidney failure, uncontrolled medical disorder that might&#xD;
             confound study results or compromise subject safety, oxygen saturation &lt;90%, or&#xD;
             requires mechanical ventilation.&#xD;
&#xD;
          -  Uncorrected anemia, methemoglobinemia, disseminated intravascular coagulation,&#xD;
             significant or uncontrolled bleeding, atypical laboratory screening tests.&#xD;
&#xD;
          -  Uncontrolled seizures, Grade 3 or 4 hepatic encephalopathy, Creutzfeldt-Jakob disease,&#xD;
             glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Active extrahepatic malignancy or survival prognosis of &lt;6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

